Abbott Molecular Inc.

Abbott Molecular Inc., a subsidiary of Abbott Laboratories, supplies molecular diagnostic analyzers, reagents, consumables, and related testing services to federal healthcare agencies as a prime contractor, competing full-and-open across GSA Federal Supply Schedules without set-aside designations.

Abbott Molecular operates as a large for-profit manufacturer of in-vitro diagnostic substances and laboratory instrumentation, headquartered in Des Plaines, Illinois. The company competes under the parent company Abbott Laboratories' established GSA schedules, primarily Invitro Diagnostics, Reagents, Test (FSS-65-VII) and Critical Analyzers, Laboratory (FSS-66-III), with no small business certifications. Recent concrete work includes a $6.09 million definitive contract awarded October 1, 2026, by the Defense Health Agency for molecular transplant, respiratory, and sexual health testing services at Brooke Army Medical Center (JBSA FT SAM HOUSTON, Texas) under a cost-per-test structure with an Alinity M platform, running through September 30, 2029; a $2.41 million delivery order from Veterans Integrated Service Network 4 for sexually transmitted infection and SARS-CoV-2 testing supplies and reagents on the Alinity M platform (September 2024–September 2026); and an $8.38 million delivery order from Veterans Integrated Service Network 21 for Alinity M reagents and consumables through March 31, 2029, both under the GSA Critical Analyzers, Laboratory schedule.

Customer concentration is heavy in the Department of Veterans Affairs, which accounts for the dominant share of both award count and dollar value. The top five customer agencies by award count—Air Force Air Education and Training Command (93 awards, $2.6 million), VISN 2 (78 awards, $54.1 million), CDC Pittsburgh (49 awards, $4.8 million), VISN 21 (42 awards, $31.9 million), and Army Medical Command (38 awards, $6.7 million)—represent 34 percent of recent awards. By potential value, the VA dominates: VISN 2 ($54.1 million across 78 awards), VISN 21 ($31.9 million, 42 awards), VISN 20 ($29.3 million, 33 awards), and VISN 9 ($20.4 million, 30 awards) together account for 27 percent of combined potential value. The Defense Health Agency ranks fifth by value ($20.2 million, 24 awards) but lower in count, indicating larger task orders.

Abbott Molecular maintains positions on two dominant GSA schedules: the Critical Analyzers, Laboratory (FSS-66-III) schedule with 184 task orders totaling $102.2 million in combined potential value, and the Invitro Diagnostics, Reagents, Test (FSS-65-VII) schedule with 138 task orders totaling $81.2 million. Additional vehicles include Army Medical Research and Materiel Command blanket purchase agreements for HIV genotyping, HIV-1 testing, and related reagent supply. The company also holds single-award BPAs with individual VISNs—VISN 19 ($3.2 million ceiling for Alinity M reagents through November 2026), VISN 2 ($8.68 million for Alinity M reagents through May 2027), and VISN 1 ($10.8 million for COVID-19, HIV, and HPV testing supplies through September 2026)—demonstrating entrenched supply relationships.

Activity has declined from a peak of 43 awards in 2022 to 7 awards in 2026 year-to-date, reflecting maturation of the Alinity M installed base and market consolidation. Twenty-five awards with ultimate completion dates in the next twenty-four months carry combined potential value of $15.6 million, presenting recompete exposure concentrated in VA VISN reagent supply and analyzer maintenance contracts. The company's award portfolio spans 870 total awards across forty distinct federal agencies since 2005, with 866 prime awards and only four sub-awards (one identified under Weems Design Studio for a molecular diagnostics analyzer maintenance task at NIAID, January 2025). Abbott Molecular executes nearly all work as a prime contractor rather than as a sub-vendor, with no named major subcontractors in the source material. The parent company, Abbott Laboratories Inc., holds the Abbott Diagnostics Division designation and operates Abbott Nutrition as a doing-business-as entity.

NAICS concentration reflects the core capability: In-Vitro Diagnostic Substance Manufacturing (346 awards), Analytical Laboratory Instrument Manufacturing (206 awards), and Surgical and Medical Instrument Manufacturing (76 awards) dominate the portfolio. PSC coding aligns with product scope—Laboratory Equipment and Supplies (276 awards), Medical and Surgical Instruments, Equipment, and Supplies (232 awards), and In Vitro Diagnostic Substances, Reagents, Test Kits and Sets (166 awards)—confirming Abbott Molecular's position as the federal government's primary supplier of Alinity M molecular diagnostic platforms and proprietary consumables to the Veterans Health Administration and Department of Defense medical research facilities.